
Kevin E Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3146503/publications.pdf Version: 2024-02-01



KEVIN E RROWN

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Extended interval BNT162b2 vaccination enhances peak antibody generation. Npj Vaccines, 2022, 7, 14. | 6.0 | 101 |
| 2 | Disease severity during SARS-COV-2 reinfection: a nationwide study. Journal of Infection, 2022, 84, 542-550. | 3.3 | 49 |
| 3 | Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine, 2022, 386, 340-350. | 27.0 | 501 |
| 4 | VITT and Second Doses of Covid-19 Vaccine. New England Journal of Medicine, 2022, 386, 95-95. | 27.0 | 38 |
| 5 | Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England. Journal of Infection, 2022, 84, 692-700. | 3.3 | 13 |
| 6 | Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 2022, 386, 1532-1546. | 27.0 | 1,709 |
| 7 | Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. Journal of Infection, 2022, 84, 814-824. | 3.3 | 8 |
| 8 | Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. Epidemiology and Infection, 2022, 150, . | 2.1 | 8 |
| 9 | Effectiveness of oral aciclovir in preventing maternal chickenpox: A comparison with VZIG. Journal of Infection, 2022, , . | 3.3 | 2 |
| 10 | Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nature Microbiology, 2022, 7, 1180-1188. | 13.3 | 39 |
| 11 | Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Eurosurveillance, 2021, 26, . | 7.0 | 34 |
| 12 | The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. Eurosurveillance, 2021, 26, . | 7.0 | 10 |
| 13 | Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ, The, 2021, 373, n1088. | 6.0 | 881 |
| 14 | Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. Journal of Infection, 2021, 82, 162-169. | 3.3 | 61 |
| 15 | Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, Marchâ^'June 2021, England. Eurosurveillance, 2021, 26, . | 7.0 | 47 |
| 16 | Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, 585-594. | 27.0 | 2,411 |
| 17 | mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. ELife, 2021, 10, . | 6.0 | 28 |
| 18 | Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet Healthy Longevity, 2021, 2, e554-e560. | 4.6 | 34 |

Kevin E Brown

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. Journal of Infection, 2021, 83, 483-489. | 3.3 | 37 |
| 20 | Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. The Lancet Healthy Longevity, 2021, 2, e811-e819. | 4.6 | 54 |
| 21 | Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nature Communications, 2021, 12, 7217. | 12.8 | 80 |
| 22 | High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. EClinicalMedicine, 2020, 28, 100597. | 7.1 | 65 |
| 23 | Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. Journal of Infection, 2020, 81, 785-792. | 3.3 | 36 |